PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling and tumor progression in BRCA1-associated cancers by Beck, Carole et al.
HAL Id: hal-02330194
https://hal.archives-ouvertes.fr/hal-02330194
Submitted on 8 Oct 2020
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
PARP3, a new therapeutic target to alter
Rictor/mTORC2 signaling and tumor progression in
BRCA1-associated cancers
Carole Beck, José Manuel Rodriguez-Vargas, Christian Boehler, Isabelle
Robert, Vincent Heyer, Najat Hanini, Laurent Gauthier, Agnès Tissier,
Valérie Schreiber, Mikael Elofsson, et al.
To cite this version:
Carole Beck, José Manuel Rodriguez-Vargas, Christian Boehler, Isabelle Robert, Vincent Heyer, et
al.. PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling and tumor progression in
BRCA1-associated cancers. Cell Death and Differentiation, Nature Publishing Group, 2019, 26 (9),
pp.1615-1630. ￿10.1038/s41418-018-0233-1￿. ￿hal-02330194￿
UN
CO
RR
EC
TE
D P
RO
OF
Cell Death & Differentiation
https://doi.org/10.1038/s41418-018-0233-1
1
ARTICLE
2 PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling
3 and tumor progression in BRCA1-associated cancers
4 Carole Beck1 ● José Manuel Rodriguez-Vargas1 ● Christian Boehler1 ● Isabelle Robert2,3,4,5 ● Vincent Heyer2,3,4,5 ●
5 Najat Hanini1 ● Laurent R. Gauthier6 ● Agnès Tissier7 ● Valérie Schreiber1 ● Mikael Elofsson8 ●
6 Bernardo Reina San Martin2,3,4,5 ● Françoise Dantzer1
7 Received: 16 March 2018 / Revised: 7 September 2018 / Accepted: 22 October 2018
8 © ADMC Associazione Differenziamento e Morte Cellulare 2018
9 Abstract
10 PARP3 has been shown to be a key driver of TGFβ-induced epithelial-to-mesenchymal transition (EMT) and stemness in
11 breast cancer cells, emerging as an attractive therapeutic target. Nevertheless, the therapeutic value of PARP3 inhibition has
12 not yet been assessed. Here we investigated the impact of the absence of PARP3 or its inhibition on the tumorigenicity of
13 BRCA1-proficient versus BRCA1-deficient breast cancer cell lines, focusing on the triple-negative breast cancer subtype
14 (TNBC). We show that PARP3 knockdown exacerbates centrosome amplification and genome instability and reduces
15 survival of BRCA1-deficient TNBC cells. Furthermore, we engineered PARP3−/− BRCA1-deficient or BRCA1-proficient
16 TNBC cell lines using the CRISPR/nCas9D10A gene editing technology and demonstrate that the absence of
17 PARP3 selectively suppresses the growth, survival and in vivo tumorigenicity of BRCA1-deficient TNBC cells,
18 mechanistically via effects associated with an altered Rictor/mTORC2 signaling complex resulting from enhanced
19 ubiquitination of Rictor. Accordingly, PARP3 interacts with and ADP-ribosylates GSK3β, a positive regulator of Rictor
20 ubiquitination and degradation. Importantly, these phenotypes were rescued by re-expression of a wild-type PARP3 but not
21 by a catalytic mutant, demonstrating the importance of PARP3’s catalytic activity. Accordingly, reduced survival and
22 compromised Rictor/mTORC2 signaling were also observed using a cell-permeable PARP3-specific inhibitor. We conclude
23 that PARP3 and BRCA1 are synthetic lethal and that targeting PARP3’s catalytic activity is a promising therapeutic strategy
24 for BRCA1-associated cancers via the Rictor/mTORC2 signaling pathway.
25Introduction
26Breast cancer susceptibility gene 1 (BRCA1) is a well-
27known tumor suppressor and women carrying a germline
28mutation in the gene have a significantly higher risk to
29develop breast and ovarian cancer. Poly(ADP-ribose)
30polymerase (PARP) inhibition by targeting PARP1 is
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31 nowadays considered as one of the most pervasive ther-
32 apeutic opportunity to sensitize BRCA1-deficient tumors in
33 a synthetic lethality approach, owing to its prominent role in
34 the maintenance of genome integrity. This attractive ther-
35 apeutic potential has encouraged pharmaceutical companies
36 to design potent PARP inhibitors resulting in several lead-
37 ing candidates that have entered clinical trials. However, the
38 PARP family consists of 17 members having distinct
39 structural features and non-redundant biological functions,
40 but sharing a highly conserved PARP catalytic domain [1].
41 Thus itQ1 is still unclear how many different PARP members
42 are targeted by the currently used PARP inhibitors [2].
43 Therefore, itQ2 appears fundamental to determine the biolo-
44 gical properties of the less-characterized PARPs and
45 explore theQ3 therapeutic benefit of their inhibition in cancer
46 therapy.Q4
47 Frequently the most aggressive BRCA1 mutation-
48 associated tumors lack expression of estrogen receptor,
49 progesterone receptor and HER2 receptor being classified as
50 triple-negative breast cancers (TNBC) [3]. These tumors
51 represent a difficult therapeutic challenge owing to their cell
52 heterogeneity, the lack of validated molecular targets and
53 the poor outcome of the patients. Thus, achieving a better
54 understanding of the signaling pathways driving TNBC is
55 determinant to identify novel therapeutic targets and
56 develop new curative strategies. It has been shown that
57 basal-like TNBC cells exploit the Rictor/mTORC2 signal-
58 ing pathway to promote tumor progression [4].
59 mTORC2 together with mTORC1 represent two struc-
60 turally distinct multiprotein complexes of the mammalian
61 target of rapamycin (mTOR), a serine/threonine kinase
62 influencing cell metabolism, proliferation, survival, and
63 tumor growth [5]. mTORC1 consists of mTOR, Raptor,
64 mLST8, and PRAS40 and is well characterized for it role in
65 protein and lipid synthesis, mitochondrial metabolism and
66 autophagy. mTORC2 comprises mTOR, mLST8, Rictor,
67 mSIN1, and Protor and functions as a critical Serine 473
68 kinase of Akt, often hyper-activated in cancers [6]. Rictor/
69 mTORC2 mediates cell survival, chemoresistance, cytos-
70 keleton reorganization, cell motility, and TGFβ-induced
71 epithelial-to-mesenchymal transition (EMT), key hallmarks
72 of the metastatic process. In this complex, Rictor is defined
73 as an essential scaffold protein required for mTORC2
74 assembly, stability, and function [7].
75 An advanced analysis of the published PARP3 expres-
76 sion profile in the panel of breast cancer cells from the
77 Cancer Cell Line Encyclopedia (CCLE) revealed a sig-
78 nificantly higher expression of PARP3 in the basal-like
79 TNBC subtypes compared to the non-TNBC (Supplemen-
80 tary Fig. 1). Initially, theQ5 DNA-dependent PARP3 was
81 described to play critical roles in the repair of double-strand
82 breaks via non-homologous end joining (NHEJ), in class
83 switch recombination, in chromosomal rearrangements by
84suppressing G4 structures, in telomere segregation and
85microtubule spindle formation during mitosis and in tran-
86scriptional regulation during development in the zebrafish
87[8–13]. Recently, PARP3 emerged as a promising ther-
88apeutic target to restrain TGFβ and ROS-driven EMT and
89limit stemness in breast cancer cells [14]. However, the
90beneficial significance of PARP3 inhibition to prevent
91tumor progression has not yet been evaluated.
92Here we examined the impact of the absence of PARP3
93and its chemical inhibition on the tumorigenicity of
94BRCA1-proficient versus BRCA1-deficient TNBC cell
95lines. We demonstrate that PARP3 inactivation selectively
96suppresses the tumor progression of BRCA1-deficient
97TNBC cells via effects associated with impaired Rictor/
98mTORC2 signaling, defective cytoskeleton organization
99and exacerbated centrosomal amplification. This study
100supports PARP3 inhibition as an encouraging targeted
101therapy option for BRCA1-deficient TNBC.
102Material and methods
103Reagents
104TGFβ2 and MG132 were purchased from Sigma-Aldrich.
105The PARP1 inhibitor Ku-0058948 and the PARP3 inhibitor
106ME0328 have been described [15–17]. The PARG inhibitor
107PDD 00017273 was purchased from Tocris Bioscience
108(Bristol, UK).
109Cell lines and cell culture
110MDA-MB231, Hs578T, and MDA-MB436 (ATCC) are
111defined as basal-like TNBC cells [18]. MDA-MB436 cell
112line harbors a 5396+1G>A BRCA1 mutation in the splice
113donor site of exon 20. MDA-MB231 and MDA-MB436
114cells were grown in RPMI supplemented with 10% fetal
115calf serum and 1% gentamicin. Hs578T were grown in
116DMEM-1g/L D-glucose supplemented with 20% fetal calf
117serum and 1% gentamicin. All cell lines were maintained at
11837 °C and 5% CO2. Flag, Flag-PARP3
WT and Flag-
119PARP3HE rescued PARP3−/−c MDA-MB436 cell lines
120were maintained in 0.2 μg/mL Puromycin-containing med-
121ium. When indicated, cells were treated with 10 ng/mL of
122TGFβ2 for 48 h before processing.
123siRNA-mediated depletion
124Gene-specific siRNAs (ON_TARGET plus smart pool) for
125PARP3 (L-009297), PTEN (J-003023), BRCA1 (J-
126003461), and the negative control siRNA (D-001810) were
127obtained from Dharmacon (Thermo Fisher Scientific). Cells
128were transfected with 50 nM siRNA using JetPrime
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129 (PolyPlus transfection) according to the manufacturer’s
130 instructions and cells were processed for the indicated
131 experiments from 48 h to 72 h later.
132 Knockout of PARP3 using CRISPR/nCas9-mediated
133 genome editing
134 Cells were co-transfected with two plasmids expressing 2
135 gRNAs targeting exon 2 and co-expressing nCas9-EGFP
136 and 2 gRNAs targeting exon 5 and co-expressing nCas9-
137 mCherry and bearing Neomycin or Hygromycin selection
138 cassettes respectively (Sup. Figure 4). Forty-eight hours
139 after transfection, EGFP+mCherry+ cells were sorted by
140 flow cytometry and cultured for 3 days in medium con-
141 taining Hygromycin (350 μg/mL) and G418 (500 μg/mL)
142 for MDA-MB231 or Hygromycin (400 μg/mL) and G418
143 (350 μg/mL) for MDA-MB436. Single colonies were
144 picked, amplified, and genotyped by PCR using primers
145 located upstream of exon 2 and downstream of exon 5
146 (Suplementary Table S1). PCR products were sequenced
147 and the absence of PARP3 was verified by western blot.
148 gRNA sequences
149 The gRNA sequences are as following: gRNA1 (GCCTC
150 AGCGGTGGAGCGGAA, Exon 2), gRNA2 (AGAGAAG
151 CGCATAATCCGCG, Exon 2), gRNA3 (GTTAGTGAT
152 GAGCTTCTGCG, Exon 5), gRNA4 (CACCATGGCCC
153 TCATGGACC, Exon 5) (Supplementary Fig. 4A). nCas9-
154 compatible gRNA pairs were selected using the CRISPR
155 design tool (http://crispr.mit.edu/).
156 Generation of PARP3-rescued cell lines
157 PARP3−/−c MDA-MB436 cells were transfected with 10 μg
158 of plasmids encoding Flag, Flag-PARP3WT or Flag-
159 PARP3HE using JetPrime. Two days after transfection,
160 cells were selected for 2 days with Puromycin (0.8 μg/mL),
161 maintained for 2 weeks under Puromycin (0.2 μg/mL) and
162 sorted for EGFP expression by flow cytometry. Expression
163 was verified by western blot.
164 Cell extracts and western blot
165 Cells were lysed by incubation on ice for 30 min in RIPA-
166 like buffer (50 mM Tris-HCl, pH 8, 1% Triton X-100,
167 0.25% Na Deoxycholate, 150 mM NaCl, 1 mM EDTA, 50
168 mM NaF, 20 mM Na pyrophosphate, 1 mM Na orthova-
169 nadate, 1 mM Pefabloc (Roche), 1X protease inhibitor
170 cocktail (Roche)). After centrifugation at 13,000 rpm at 4 °C
171 for 15 min, cleared suspension was quantified by Bradford
172 protein assay. Proteins were analysed by SDS-PAGE
173 and immunoblotting using the appropriate antibodies
174(Supplementary Table S2). When analysing the impact of
175the ME0328, cells were treated with the compound for 24 h
176before lysis.
177Immunoprecipitation experiments
178Equivalent amounts of RIPA-like cell extracts (1.5–2 mg
179total proteins) were diluted in dilution buffer DB (20 mM
180Tris-HCl, pH 7.5, 0.1% NP40, 150 mM NaCl, 1 mM
181Pefabloc) and pre-cleared by incubation on protein A/G
182separose beads for 1 h at 4 °C before incubation with the
183indicated antibodies (Supplementary Table S2) overnight at
1844 °C followed by 2 h incubation at 4 °C with protein A/G
185sepharose (GE Healthcare, Little Chalfont, UK). Beads
186were washed twice with DB containing 250 mM NaCl and
187twice with DB containing 150 mM NaCl. Beads were then
188resuspended in Laemmli buffer and analysed by SDS-
189PAGE and immunoblotting as above.
190When analyzing the ADP-ribosylation of GSK3β, cells
191were pre-treated with the PARG inhibitor PDD 00017273 at
1921 μM for 2 h to prevent from poly(ADP-ribose) degradation
193and the compound was maintained throughout. The PARP
194inhibitor Ku-0058948 was added during lysis at 100 nM to
195prevent from unspecific ADP-ribosylation during lysis.
196In vivo ubiquitination assay
197Cells were transfected with 5 μg of HA-Ubiquitin [19] for
19848 h and either mock-treated or treated with MG132 (10
199μM) for 12 h before lysis using the RIPA-like buffer.
200Equivalent amounts of total protein extracts (2 mg) were
201processed for immunoprecipitation as above using the anti-
202Rictor antibody (Supplementary Table S2). Ubiquitinated
203Rictor was revealed by western blotting using an anti-HA
204antibody (Supplementary Table S2).
205Colony-forming assay and cell proliferation
206siRNA-depleted cells were collected 72 h after siRNA
207transfection. Cells were seeded in triplicates at 1000 cells
208for MDA-MB231, 1500 cells for MDA-MB436 and 1500
209cells for HS578T in 100-mm culture dishes. PARP3−/−
210MDA-MB231 clones were seeded in triplicates at the
211number of 1000 cells and PARP3−/− MDA-MB436 clones
212were seeded at the number of 3000 cells in 100-mm culture
213dishes. When analysing the impact of ME0328, cells were
214pre-incubated with the compound for 24 h before seeding
215and the medium with the compound was renewed every 48
216h. From 7 to 15 days later, cells were fixed for 30 min in
217formaldehyde (3.7%), stained with crystal violet (0.1%) and
218colonies were scored. Statistical analyses were determined
219by ANOVA tests as indicated by p-values using StatView
220software. To determine cell growth rate, cells were seeded
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221 into 6-well plates (40,000 cells/well for MDA-MB231 cells
222 and 80,000 cells/well for MDA-MB436 cells) in triplicate
223 and counted daily for 4 days.
224 Immunofluorescence microscopy and fluorescent
225 in situ hybridization (FISH)
226 F-actin labeling was performed using Alexa Fluor 568
227 Phalloidin (Thermo Fisher Scientific) according to the
228 manufacturer’s protocol. For immunofluorescence, cells
229 were fixed in 4% formaldehyde and stained with the indi-
230 cated antibodies as described [8]. Metaphase spreads and
231 analysis of telomere aberrations by FISH were performed as
232 described [8].
233 GTPase activity assays
234 Cells were serum-starved for 24 h and stimulated with
235 TGFβ2 (10 ng/mL) for 5 h. GTP-bound RhoA and Rac1 and
236 total protein contents were detected using Active Rho
237 (16116) and Active Rac1 (16118) pull-down and detection
238 kits (Thermo Fisher Scientific) according to manufacturer’s
239 instructions.
240 Scratch wound assays
241 A linear wound was created on confluent monolayers of
242 cells using a sterile 200 μl pipette tip. Cells were placed in
243 an environment controlled wide field microscope Leica
244 DMIRE 2 microscope equipped with a Photometrics Prime
245 sCMOS camera and the Imaging capture software Meta-
246 morph, and imaged every 20 min for 24 h using a ×10 phase
247 contrast objective.
248 In vivo tumorigenicity experiments
249 Animal protocols were approved by the Ministry of Higher
250 Education in Research and Innovation and the local ethics
251 committee Cremeas. Female athymic nude mice (S/SOPF
252 SWISS NU/NU) were purchased from Charles Rivers
253 Laboratories. For xenograft studies, 3.5 × 106 MDA-MB231
254 and 5 × 106 MDA-MB436 cells in 50% of Matrigel
255 (Corning) were implanted subcutaneously into both flanks
256 of the 7-week-old nude mice upon xylazine (50 mg/kg)/
257 ketamine (3 mg/kg) anesthesia. Tumor volumes were cal-
258 culated from caliper measurements by length (L) and width
259 (W) by using the formula: Tumor volume (V mm3)=
260 length × (Width)2/2.
261 In vitro PARylation assays
262 In vitro PARylation assays were performed using immu-
263 nopurified Flag-PARP3WT and Flag-PARP3HE in activity
264buffer containing α-32PNAD and DNase I activated calf
265thymus DNA as described [8].
266Results
267PARP3 silencing impairs survival of BRCA1-deficient
268or BRCA1-depleted TNBC cells
269Tankyrase 1 inhibition was found to be selectively lethal
270in the context of BRCA1 deficiency [20]. Therefore, we
271investigated the possibility that targeting PARP3, an
272activator of Tankyrase 1 [8], may have a similar effect.
273We used breast cancer cells of the basal-like TNBC sub-
274types because of the predominant expression of PARP3
275(Supplementary Fig. 1) [14]. We first compared the sen-
276sitivity of the BRCA1-proficient (MDA-MB231, Hs578T)
277and BRCA1-deficient (MDA-MB436) cells to the deple-
278tion of PARP3 by clonogenic survival assays. PARP3
279knockdown was significantly more lethal in the BRCA1-
280deficient cells (Fig. 1a). Consistent with this, knockdown
281of both PARP3 and BRCA1 in the BRCA1-proficient
282cells (MDA-MB231 and Hs578T) resulted in significantly
283reduced cell survival when compared to cells transfected
284with control siRNA or with each siRNA alone (Fig. 1b, c).
285A similar lethal impact of PARP3 silencing was observed
286in the BRCA1-deficient breast cancer cell line HCC1937
287and in the ovarian cancer cell line UWB1.289, when
288compared to the isogenic cell lines with restored BRCA1
289expression (Supplementary Fig. 3 and 7A). We conclude
290that ARP3 depletion is lethal in a BRCA1-deficient
291background.
292PARP3 silencing exacerbates centrosome
293amplification and genome instability in BRCA1-
294deficient TNBC cells
295Increased lethality associated with the combined defi-
296ciency of BRCA1 and Tankyrase 1 was previously spe-
297cified by enhanced centrosome amplification [20]. PARP3
298long isoform localizes to the daughter centriole and reg-
299ulates mitotis [8, 21]. Therefore, we interrogated on the
300consequence of PARP3 depletion on centrosome ampli-
301fication in the BRCA1-proficient Hs578T cells versus the
302BRCA1-deficient MDA-MB436 cells. Although PARP3
303depletion moderately increased the percentage of cells
304with centrosome amplification in the Hs578T cells
305(Fig. 2a, b), this phenotype was markedly exacerbated in
306the MDA-MB436 cells (Fig. 2a–c). Centrosome amplifi-
307cation often results in the formation of multiple nuclei
308within a single cell. Accordingly, the depletion of PARP3
309intensified the percentage of cells with multiple nuclei in
310the MDA-MB436 (19.2%) versus the Hs578T cells
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311 (12.7%) (Fig. 2d). AsQ6 centrosome amplification has been
312 linked with genome instability in breast cancer [22], we
313 scored telomeric aberrations and the emergence of
314 micronuclei as indicators of overall chromosome
315 instability. Although the depletion of PARP3 did not
316 aggravate the telomere instability detected in the MDA-
317 MB436 cells, it significantly increased the formation of
318 micronuclei in the MDA-MB436 cells only (Fig. 2e, f).
319 Together, these findings revealed that the depletion of
320 PARP3 results in supernumerary centrosomes and
321 increased genome instability markedly in BRCA1-
322 deficient cells.
323Knockout of PARP3 impairs proliferation, survival,
324and tumor progression in BRCA1-deficient TNBC
325cells
326To further clarify the function of PARP3 in breast cancer
327associated with BRCA1 deficiency, we inactivated PARP3
328in MDA-MB231 and MDA-MB436 cells using a double
329nCas9(D10A) strategy (Supplementary Fig. 4 and [23]). For
330each cell line, three independent PARP3−/− clones were
331generated (Supplementary Fig. 5, Fig. 3a, b). The absence
332of PARP3 only moderately impaired the proliferation rate of
333the MDA-MB231 cells, whereas reduced markedly the
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Fig. 1 PARP3 silencing is more lethal in the context of BRCA1
deficiency. a Clonogenic survival of MDA-MB231 and Hs578T breast
cancer cells expressing a wild-type BRCA1 compared to the BRCA1-
deficient breast cancer cell line MDA-MB436 after transfection with
the indicated siRNA. The survival of the si-control (siCTL) cells was
set as 100%. Experiments were performed more than three times
giving similar results. Mean values of triplicates ± SD are indicated.
*p < 0.05; ***p < 0.001. (Insets) The efficiency of the depletions for
the experiments shown was verified by western blot analysis 72 h post
siRNA transfection. b, c Clonogenic survival of MDA-MB231 and
Hs578T cells after transfection with the indicated siRNA. Note the
additive effect of the co-depletion of both PARP3 and BRCA1 com-
pared to the relative single depletions. The survival of the si-control
(siCTL) cells was set as 100%. Experiments were performed more
than three times giving similar results. Mean values of triplicates ± /-
SD are indicated. ***p < 0.001. The efficiency of depletions was
verified by RT-qPCR (Supplementary Fig. 2)
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334 proliferation rate of the MDA-MB436 cells (Fig. 3c, d). In
335 support of our initial observations (Fig. 1), PARP3 knock-
336 out only slightly diminished the survival of MDA-MB231
337 cells but strikingly reduced the survival of the MDA-
338 MB436 cells (Fig. 3e, f). Reciprocally, silencing of BRCA1
339 increased lethality in the two PARP3−/−1 and PARP3−/−3
340MDA-MB231 clones, whereas the depletion of PTEN had
341no additive effect (Supplementary Fig. 6A).
342We then analysed the impact of PARP3 knockout on the
343in vivo tumorigenicity of the MDA-MB231 and MDA-
344MB436 cells subcutaneously xenografted into nude mice.
345Whereas PARP3 knockout MDA-MB231 cells exhibited
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Fig. 2 PARP3 silencing exacerbates centrosome amplification and the
appearance of polynuclear cells and induces genome instability in
BRCA1-deficient cells. a Quantification of the percentage of total cells
displaying more than two centrioles in Hs578T compared to MDA-
MB436 cells after transfection with the indicated siRNA. Experiments
were performed three times. Mean values of the triplicates ± SD are
indicated. *p < 0.05; **p < 0.01; ***p < 0.001. b, c Detailed distribu-
tion of the percentage of cells displaying from 3 to > 10 centrioles in
Hs578T and MDA-MB436 cells. Whereas Hs578T cells displayed up
to 6 centrosomes/cells upon PARP3 silencing, this number raised to
over 10 centrosomes in 8% of the MDA-MB436 cells. An average of
500 cells per cell line was scored in more than 20 randomly selected
fields. Results are averages from three independent experiments. Mean
values ± SD are indicated. *p < 0.05; **p < 0.01. A representative
image of the centrosome amplification observed in a PARP3-silenced
MDA-MB436 cell (siPARP3) versus a control (siCTL) cell is shown.
Scale bars= 1 μm. Centrosomes are stained with p34cdc2 (green) and
cells are counterstained with DAPI (blue). d Quantification of the
percentage of cells with multiple nuclei in Hs578T and MDA-MB436
cells transfected with the indicated siRNA. Cells with two or more
nuclei were scored. An average of 500 cells per cell line was scored in
more than 20 randomly selected fields. Results are averages from three
independent experiments. Mean values ± SD are indicated. *p < 0.05;
**p < 0.01. e Quantification of telomeric aberrations expressed as
percentages of telomere aberrations per metaphase in MDA-MB231
and MDA-MB436 cells transfected with the indicated siRNA. Telo-
mere aberrations were detected by FISH on metaphase spreads. Thirty
cells were scored for each independent condition. Mean values ± SD
are indicated. *p < 0.05; ***p < 0.001. f Quantification of the per-
centage of cells with micronuclei in Hs578T and MDA-MB436 cells
transfected with the indicated siRNA. An average of 500 cells per cell
line was scored in more than 20 randomly selected fields. Results are
averages from three independent experiments. Mean values ± SD are
indicated. **p < 0.01
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346 notably reduced tumorigenic potential with a higher effect
347 in the PARP3−/−2 clone compared to the parental MDA-
348 MB231 cells (Fig. 3g), the tumorigenic potential was totally
349 abolished in the three PARP3−/−a, PARP3−/−b, PARP3−/−c
350 MDA-MB436 cells (Fig. 3h). In line with this, the silencing
351 of PARP3 abolished the tumorigenic potential of the
352 BRCA1-mutated HCC1937 cells and reciprocally the
353 silencing of BRCA1 significantly reduced the tumorigenic
354 potential of the PARP3−/−1 MDA-MB231 cells (Supple-
355 mentary Fig. 6B and 7B).
356Altogether, these data confirmed that the absence of
357PARP3 is selectively lethal with BRCA1 deficiency in three
358different TNBC cell lines.
359Re-expression of PARP3, but not a catalytic mutant,
360rescues proliferation, survival and in vivo
361tumorigenicity in a BRCA1-deficient background
362To evaluate the functional importance of PARP3’s catalytic
363activity in the context of BRCA1 deficiency and to exclude
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Fig. 3 Knockout of PARP3 significantly reduces cell growth and
survival and suppresses tumor growth in the context of BRCA1
deficiency. a, bWestern blot analysis of PARP3 expression in the wild
type (WT) and three PARP3−/−1, PARP3−/−2, PARP3−/−3 MDA-
MB231 clones as well as in the wild type (WT) and three PARP3−/−a,
PARP3−/−b, PARP3−/−c MDA-MB436 clones selected upon
screening and sequence analysis. Actin is used as loading control. The
remaining lower band is unspecific and randomly detected by the
PARP3 antibody depending on the cell lines used. c, d Graphs com-
pare proliferation rates between wild-type MDA-MB231 (WT) and
PARP3−/−1, PARP3−/−2, PARP3−/−3 MDA-MB231 cell lines and
between wild-type MDA-MB436 (WT) and PARP3−/−a, PARP3−/−b,
PARP3−/−c MDA-MB436 clones. Experiments were performed three
times giving similar results. Mean values of triplicates ± SD are indi-
cated. *p < 0.05; **p < 0.01; ***p < 0.001. e, f Survival is expressed as
the percentage of colonies formed in the PARP3−/−1, PARP3−/−2,
PARP3−/−3 MDA-MB231 clones versus the parental MDA-
MB231 (WT) cell line set to 100% and in the PARP3−/−a,
PARP3−/−b, PARP3−/−c MDA-MB436 clones versus the wild-type
MDA-MB436 (WT) set to 100%. Results represent the mean values of
three independent experiments ± SD. *p < 0.05; ***p < 0.001. g, h
Relative tumor growth curves of xenografts derived from the wild-type
(WT) MDA-MB231 cells or the three PARP3−/−1, PARP3−/−2,
PARP3−/−3 MDA-MB231 knockout cell lines and from the wild-
type (WT) MDA-MB436 cells versus the PARP3−/−a, PARP3−/−b,
PARP3−/−c MDA-MB436 clones. Mean RTV (relative tumor volume)
(n= 6 individual mice) are expressed compared to tumor volumes on
day 4 for MDA-MB231 series and on day 18 for the MDA-MB436
series. Insets, representative images of the tumors collected at the end
of the experiment are shown. For g, WT MDA-M231cells were
implanted on the left flank, PARP3−/−1 cells were implanted right. For
h, WT MDA-MB436 cells were implanted left, PARP3−/−a were
implanted right
PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling and tumor progression in. . .
UN
CO
RR
EC
TE
D P
RO
OF
364 potential off-targets effects of the CRISPR/Cas9 system, we
365 re-expressed Flag-PARP3 (Flag-PARP3WT), a catalytically
366 inactive mutant (Flag-PARP3HE) or a Flag peptide alone in
367 PARP3−/−c MDA-MB436 cells. Flag-PARP3HE was gen-
368 erated by introducing mutations (H376A and E508A) in the
369 ADP-ribosyl transferase (ART) domain of PARP3. The
370effectiveness of this substitution was verified using an
371in vitro auto-ADP-ribosylation assay (Fig. 4a) and both
372Flag-tagged proteins were efficiently expressed in the
373restored cell lines (Fig. 4b). As expected, PARP3−/−c
374MDA-MB436 cells expressing the Flag tag alone displayed
375reduced growth rate compared to the parental cell line
Fig. 4 Defective proliferation, survival, and in vivo tumorigenicity
of the PARP3 knockout MDA-MB436 cells are rescued by the
re-expression of the catalytically active PARP3 but not by the re-
expression of a catalytically dead PARP3. a Radioactive in vitro auto-
ADP-ribosylation assay showing the automodification of Flag-
PARP3WT, although no automodification is detected for the dead
Flag-PARP3HE mutant. Immunopurified Flag-PARP3WT and Flag-
PARP3HE were incubated in PARP activity buffer containing DNAse
I-treated DNA and α-32P-NAD+. The addition of Ku-0058948
(250 nM) inhibits PARP3 [8]. b Western blot analysis of PARP3
expression in the wild type (WT) and PARP3−/−c MDA-MB436 cells
with a stable expression of either the Flag control (Flag), Flag-
PARP3WT or Flag-PARP3HE. GAPDH is used as loading control. c
Graphs compare proliferation rates between the parental MDA-MB436
(WT) and the PARP3−/−c MDA-MB436 cell lines expressing either
the Flag control (Flag), Flag-PARP3WT or Flag-PARP3HE fusion
proteins. Experiments were performed three times giving similar
results. Mean values of triplicates ± SD of a representative experiment
are indicated. d Survival is expressed as the percentage of colonies
formed in the PARP3−/−c MDA-MB436 cell lines expressing either
the Flag control (Flag), Flag-PARP3WT or Flag-PARP3HE versus the
parental MDA-MB436 cells (WT) set to 100%. Results represent the
mean values of three independent experiments ±SD. *p < 0.05; **p <
0.01; ***p < 0.001. Insets, an illustration of a representative experi-
ment is shown. e Relative tumor growth curves of xenografts derived
from the wild type (WT) MDA-MB436 cells, and the PARP3−/−c
MDA-MB436 cell lines expressing either the Flag control (Flag), Flag-
PARP3WT or Flag-PARP3HE fusion proteins. Mean RTV ± SD (n= 6
individual mice) are expressed compared to tumor volumes on day 13
for all cell lines. *p < 0.05; **p < 0.01. Insets, representative images of
the tumors collected at the end of the experiments. Illustration left,
WT cells were implanted on the left flank, PARP3−/−c-Flag cells were
implanted right. Illustration right, PARP3−/−c-Flag-PARP3WT cells
were implanted left, PARP3−/−c-Flag-PARP3HE were implanted right
C. Beck et al.
UN
CO
RR
EC
TE
D P
RO
OF
376 (WT). Whereas a partial rescue of the proliferation defect
377 was observed in the PARP3−/−c MDA-MB436 cells
378 expressing Flag-PARP3WT, no rescue was observed with
379 the Flag-PARP3HE mutant (Fig. 4c). To validate these
380 observations further, we analysed the impact on cell survi-
381 val using clonogenic assays (Fig. 4d). In support of Fig. 3,
382 PARP3−/−c MDA-MB436 cells expressing the Flag tag
383 only exhibited profound decrease in cell survival compared
384 to the parental cell line. While a substantial rescue was
385 obtained in the PARP3−/−c MDA-MB436 cells expressing
386 Flag-PARP3WT, no survival was retrieved in the PARP3−/−c
387 MDA-MB436 cells expressing Flag-PARP3HE. Next, we
388 analyzed the in vivo tumorigenic potential of the rescued
389 cell lines (Fig. 4e). PARP3−/−c MDA-MB436 cells
390 expressing the Flag tag displayed a significantly decreased
391 tumorigenic potential when compared to the parental cell
392 line. Similarly, re-expression of Flag-PARP3HE had no
393 effect on tumor growth. On the contrary, re-expression of
394 Flag-PARP3WT exacerbated tumor growth. Together, these
395 results demonstrate that the catalytic activity of PARP3 is
396 required for tumor growth in a BRCA1-deficient
397 background.
398 Knockout of PARP3 attenuates the oncogenic
399 Rictor/mTORC2 signaling in the BRCA1-deficient
400 TNBC cells
401 In cancer progression, proliferation, survival, and centro-
402 some amplification are highly dependent on the activation
403 status of the oncogenic Rictor/mTORC2 signaling pathway.
404 mTORC2 mediates the phosphorylation of Akt on Ser473
405 and contributes to BRCA1-mediated tumorigenesis
406 [24, 25].
407 To examine the role of PARP3 in the Rictor/mTORC2
408 pathway in the context of BRCA1 deficiency, we tested the
409 basal phosphorylation status of Akt on Ser 473 (Fig. 5a).
410 Consistent with published reports, BRCA1-deficient MDA-
411 MB436 showed constitutive levels of p-Akt(S473) com-
412 pared to undetectable levels in the MDA-MB231. Knockout
413 of PARP3 significantly reduced the amount of p-Akt(S473)
414 in the MDA-MB436 suggesting that PARP3 promotes the
415 phosphorylation of Akt. To verify this observation further,
416 we analysed the autophosphorylation of mTORC2 on Ser
417 2481 defined as a marker for intact mTORC2 activity [26].
418 We detected increased levels of p-mTORC2(S2481) in the
419 parental MDA-MB436 cells compared to the MDA-MB231
420 cells but no visible impact was seen in the absence of
421 PARP3. We then analysed the expression of Rictor, a
422 mandatory cofactor of mTORC2 required for its stability
423 and integrity [6]. Similarly to PARP3, RICTOR transcript
424 levels are higher in TNBC versus non-TNBC cells (Sup-
425 plementary Fig. 1). The absence of PARP3 did not affect
426 the expression of Rictor in the MDA-MB231 cells, but
427induced a notable decrease of Rictor expression in the
428MDA-MB436 cells. In contrast, the absence of PARP3 did
429not affect the mTORC1-mediated phosphorylation of
430p70S6K on Thr 389 indicating functional mTORC1 activity
431[26].
432Next, to evaluate the contribution of PARP3 activity, we
433analysed the status of p-Akt(S473) in the MDA-MB436
434cells expressing either Flag control, Flag-PARP3WT or Flag-
435PARP3HE (Fig. 5b). Consistent with the above results,
436PARP3−/−c MDA-MB436 cells expressing the Flag tag
437only exhibited strong decrease in the basal level of p-Akt
438(S473) compared to the WT MDA-MB436 cells. Although
439the exogenous expression of Flag-PARP3WT rescued p-Akt
440(S473) levels, no rescue was detected upon re-expression of
441the dead Flag-PARP3HE mutant. Similarly, we detected the
442reduced expression of Rictor in the PARP3−/−c MDA-
443MB436 cells expressing the Flag tag only compared to the
444WT MDA-MB436 cells. Whereas the re-expression of Flag-
445PARP3WT restored Rictor expression to a WT level, no
446rescued expression was seen in the PARP3−/−c MDA-
447MB436 complemented with Flag-PARP3HE. We also ana-
448lysed the phosphorylation status of GSK3β on Ser 9, a
449target of activated Akt [27]. We observed reduced p-GSK3β
450(S9) levels in the PARP3−/−c MDA-MB436 cells expres-
451sing the Flag tag only compared to the WT cells. Restored
452p-GSK3β(S9) levels were seen in the PARP3−/−c MDA-
453MB436 cells expressing Flag-PARP3WT but not in the
454PARP3−/−c MDA-MB436 cells expressing Flag-PARP3HE.
455In support of these data, we confirmed reduced Rictor, p-
456Akt(S473) and p-GSK3β(S9) levels in the HCC1937 cells
457upon PARP3 silencing and in the two PARP3 knockout
458MDA-MB231 clones upon BRCA1 silencing while PTEN
459silencing had no impact (Supplementary Fig. 6C and 7C).
460We conclude that in BRCA1-deficient cells specifically,
461PARP3 activity promotes Rictor/mTORC2 signaling and its
462inhibition efficiently represses this tumorigenic pathway.
463PARP3 interacts with and ADP-ribosylates GSK3β,
464and limits the ubiquitination of Rictor
465In cancer cells, the levels of Rictor are regulated by its
466GSK3β-dependent ubiquitination and proteasomal degra-
467dation [28]. Moreover, GSK3β has been identified in pro-
468teome wide identification of PARP3 targets [29]. To
469understand the biochemical basis of PARP3’s contribution
470in Rictor/mTORC2 signaling in BRCA1-mutated cells, we
471investigated the association of PARP3 with GSK3β. We
472identified efficient co-immunoprecipitation of GSK3β with
473Flag-PARP3 in the PARP3−/−c MDA-MB436 cells
474(Fig. 6a). To evaluate the role of ADP-ribosylation, we
475measured the in vivo levels of ADP-ribosylated GSK3β
476immunoprecipitates using an anti-poly(ADP-ribose) anti-
477body. We detected a significant basal ADP-ribosylation of
PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling and tumor progression in. . .
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478 GSK3β in the MDA-MB436 cells that was suppressed upon
479 PARP inhibition (Fig. 6b and Supplementary Fig. 8). To
480 further interrogate on the contribution of PARP3 in the
481 ubiquitination of Rictor, we compared the levels of ubi-
482 quitinated Rictor immunoprecipitates in the PARP3−/−c-
483 MDA-MB436 versus the PARP3−/−1-MDA-MB231 cells.
484 Strikingly, the absence of PARP3 led to an apparent
485 increase in the ubiquitination levels of Rictor in the
486 PARP3−/−c-MDA-MB436 cells only (Fig. 6c). Together,
487 these data suggest that in BRCA1-deficient cells, PARP3
488 interacts with and ADP-ribosylates GSK3β to restrain the
489 ubiquitination of Rictor.
490Knockout of PARP3 decreases TGFβ-dependent Rac1
491activation and lamellipodia formation in BRCA1-
492deficient TNBC cells
493TGFβ-induced activation of mTORC2 and phosphorylation
494of Akt at Ser473 promotes actin cytoskeleton reorganization
495and cell migration via a mechanism implicating the small
496Rho/Rac1-type GTPases [30, 31]. PARP3 drives TGFβ-
497induced EMT and cell migration in breast cancer cells [14].
498Therefore, we questioned on the contribution of PARP3 in
499these oncogenic events in the context of BRCA1 deficiency.
500First, we evaluated the role of PARP3 in the TGFβ-induced
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Fig. 5 The knockout of PARP3 mitigates the oncogenic mTORC2/Akt
signaling pathway in BRCA1-deficient breast cancer cells. a Equiva-
lent amounts of total cell extracts of the parental MDA-MB231 (WT)
and the two PARP3−/−1 and PARP3−/−3 MDA-MB231 cell lines and
from the wild-type (WT) MDA-MB436 cells versus the PARP3−/−b
and PARP3−/−c MDA-MB436 clones were immunoblotted with anti-
bodies against p-Akt(S473) and Akt, p-mTOR(S2481) and mTOR,
and Rictor as markers of mTORC2 activity and against p-p70S6K
(T389) as a marker of mTORC1 activity. Actin was used as loading
control (left panel). The relative signal intensities of p-Akt(S473)
versus Akt, p-mTOR(S2481) versus mTOR, p-p70S6K (T389) versus
p70S6K and Rictor versus actin were measured in three independent
experiments using ImageJ (right panel). Mean values ± SD are
indicated. *p < 0.05; **p < 0.01. b Reintroduction of Flag-PARP3WT
in the PARP3−/−c MDA-MB436 cell line restores the constitutive
induction of p-Akt(S473), p-GSK3β(S9) and Rictor levels, but not the
reintroduction of the dead Flag-PARP3HE mutant. Equivalent amounts
of total cell extracts of the parental MDA-MB436 (WT) and the
PARP3−/−c MDA-MB436 cell lines expressing either the Flag control
(Flag), Flag-PARP3WT or Flag-PARP3HE were immunoblotted with
antibodies against p-Akt(S473), Akt, Rictor, p-GSK3β(S9), GSK3β,
and actin used as loading control (left panel). The relative signal
intensities of p-Akt(S473) versus Akt, p-GSK3β(S9) versus GSK3β
and Rictor versus actin were measured in three independent experi-
ments using ImageJ (right panel). Mean values ± SD are indicated.
*p < 0.05; **p < 0.01
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501 phosphorylation of Akt in our MDA-MB436 versus the
502 MDA-MB231 cells (Fig. 7a). Relative to TGFβ-untreated
503 cells, both MDA-MB231 and MDA-MB436 cultures trea-
504 ted with TGFβ displayed increased levels of p-Akt(S473),
505 but these inductions were less pronounced in the PARP3
506 knockout clones. Thus, the absence of PARP3 attenuates
507 the TGFβ-dependent activation of Rictor/mTORC2 inde-
508 pendently of the BRCA1 context. To investigate this result
509 further, we measured TGFβ-induced RhoA and Rac1
510 GTPase activities in our cell models (Fig. 7b). Efficient
511 TGFβ-induced GTP loading of RhoA was detected in both
512 MDA-MB231 and MDA-MB436 cells. A similar weak
513 decrease was observed in both PARP3 knockout clones
514 suggesting a faint contribution of PARP3 in the activation
515 of RhoA independently of the BRCA1 context. In contrast,
516 MDA-MB436 cells displayed a notably higher TGFβ-
517 induced GTP loading of Rac1 relative to the MDA-MB231
518 cells suggesting a specific hyperactivation of Rac1 in
519BRCA1-deficient cells. This induction was absent in the
520two PARP3−/−b and PARP3−/−c MDA-MB436 clones.
521Conversely, the absence of PARP3 had no consequence on
522the induction of Rac1 in the MDA-MB231 cells. Hence,
523TGFβ-induced Rac1 activity is profoundly impaired in the
524absence of PARP3 in the context of BRCA1 deficiency.
525Rac1 signaling promotes actin filament polymerization at
526the leading edge of the cancer cells forming lamellipodia-
527like protrusions, increasing cell migration [32]. Rictor/
528mTORC2 converge on Rac1 to drive cell motility [33].
529Therefore, we investigated whether PARP3 regulates
530changes in the actin cytoskeleton by staining F-actin
531(Fig. 7c). TGFβ treatment resulted in the appearance of
532lamellipodia in the MDA-MB436 cells while no such
533structures were detected in the MDA-MB231 cells. In
534agreement with impaired Rac1 activation, the knockout of
535PARP3 significantly reduced the extent of lamellipodia
536formation in the two PARP3−/−b and PARP3−/−c
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Fig. 6 PARP3 interacts with GSK3β and selectively restrains the
ubiquitination of Rictor in BRCA1-deficient breast cancer cells. a Co-
immunoprecipitation of GSK3β with Flag-PARP3 but not with the
Flag control. Cell extracts from PARP3−/−c MDA-MB436 cell lines
expressing either the Flag control (Flag) or Flag-PARP3WT were
immunoprecipitated with an anti-Flag antibody and analysed by
western blotting using successively anti-GSK3β, anti-Flag, and anti-
actin antibodies. Input corresponds to 1/10 of the total amount of cell
extract used for immunoprecipitation. b GSK3β is ADP-ribosylated in
the BRCA1-mutated MDA-MB436 cells. MDA-MB436 cell extracts
were immunoprecipitated with either a control antibody or an anti-
GSK3β antibody in the absence or in the presence of the PARP
inhibitor Ku-0058948. ADP-ribosylated GSK3β was revealed using an
anti-poly(ADP-ribose) antibody and an anti-GSK3β antibody. Input
corresponds to 1/10 of the total amount of cell extract used for
immunoprecipitation. c In vivo ubiquitination assay: the absence of
PARP3 enhances the ubiquitination of Rictor in the BRCA1-mutated
MDA-MB436 cells but not in the BRCA1-wild-type MDA-MB231
cells. The parental (WT) and the PARP3−/−1 MDA-MB231 cells as
well as the parental (WT) and the PARP3−/−c MDA-MB436 cells were
transfected with HA-Ubiquitin and either mock-treated or treated with
10 μM MG132 for 12 h to inhibit proteasomal degradation. Rictor
immunoprecipitates were blotted successively with an anti-HA anti-
body to detect ubiquitinated Rictor and an anti-Rictor antibody to
detected imunopurified Rictor. The weaker detection of Rictor in line 4
is due to steric hindrance caused by the enhanced ubiquitination
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537 MDA-MB436 clones. No effect was seen in the PARP3−/−1
538 and PARP3−/−3 MDA-MB231 clones. We conclude that the
539 absence of PARP3 impairs the Rac1-mediated formation of
540 lamellipodia structures in the context of BRCA1 deficiency.
541 Consequently, we compared the motility of our wild-type
542 and PARP3-knockout cell models (Fig. 7d). The absence of
543 PARP3 decreased cell migration independently of the
544 BRCA1 context.
545Chemical inhibition of PARP3 recapitulates the
546effects of the genetic disruption of PARP3
547To further validate the impact of PARP3 inhibition in
548BRCA1-deficient TNBC cells, we used the cell-permeable
549PARP3-specific inhibitor, ME0328 [16]. We first compared
550the sensitivity of the MDA-MB231 and MDA-MB436 cells
551to increasing doses of ME0328 by clonogenic assays
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Fig. 7 The knockout of PARP3 diminishes the TGFβ-dependent
Rac1 activation and lamellipodia formation in BRCA1-deficient
breast cancer cells. a The parental MDA-MB231 (WT) and the two
PARP3−/−1 and PARP3−/−3 MDA-MB231 knockout cell lines and the
wild-type (WT) MDA-MB436 cells versus the PARP3−/−b and
PARP3−/−c MDA-MB436 clones were either mock-treated (CTL) or
stimulated with TGFβ for 48 h (+TGFβ). Equivalent amounts of total
cell lysates were immunoblotted with antibodies against p-Akt(S473),
Akt and actin as loading control. b The parental MDA-MB231 (WT)
and the two PARP3−/−1 and PARP3−/−3 MDA-MB231 knockout
cell lines and the wild-type (WT) MDA-MB436 cells versus the
PARP3−/−b and PARP3−/−c MDA-MB436 clones were stimulated
with TGFβ for 48 h. Active GTP-bound RhoA or active GTP-bound
Rac1 were isolated using GST-Rhotekin-RBD-Sepharose, and detec-
ted by immunoblotting using antibodies against RhoA and Rac1,
respectively. Total abundance of RhoA and Rac1 was analysed in the
input using the appropriate antibodies. c The parental MDA-MB231
(WT) and the two PARP3−/−1 and PARP3−/−3 MDA-MB231 knock-
out cell lines and the wild-type (WT) MDA-MB436 cells versus the
PARP3−/−b and PARP3−/−c MDA-MB436 clones were stimulated
with TGFβ for 48 h and immunostained with Alexa Fluor 647 Phal-
loidin (red) to examine F-actin stress fibers and lamellipodia formation
indicated by white arrows. Nuclei are counterstained with DAPI
(blue). d Analysis of video recording of the in vitro scratch-wounds.
The percentage of wound closure was calculated by the mean ± SD of
five wound widths per condition taken at different time points
throughout 24 h and performed in three independent experiments. The
percentage of wound closure for the parental cells was set to 100%.
*p < 0.05; **p < 0.01. Scale bars= 10 μm
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552 (Fig. 8a). At all doses of ME0328 used, the inhibition of
553 PARP3 caused significantly higher lethality in the BRCA1-
554 deficient cells then in the BRCA1-wild-type cells (black
555 bars). Similar result was observed in the HCC1937 cells
556 (Supplementary Fig. 7A). Notably, this effect was not
557 detected in the PARP3−/−c MDA-MB436 cells and not
558 significant at the highest dose in the PARP3−/−1 MDA-
559 MB231 cells (gray bars) revealing the specificity of
560 ME0328 in vivo.
561 We then analysed the sensitivity of the MDA-MB436
562 cells to the compound compared to the PARP3−/−c MDA-
563MB436 cells expressing either Flag or Flag-PARP3WT
564(Fig. 8b). ME0328 significantly reduced survival of the
565control MDA-MB436 cells and the PARP3−/−c MDA-
566MB436 cells restored with Flag-PARP3WT, but had no
567impact on the PARP3−/−c MDA-MB436 cells expressing
568the Flag tag only, confirming the selectivity to PARP3
569inhibition.
570To determine the inhibitory effect of ME0328 on Rictor/
571mTORC2 signaling, we analysed the status of p-Akt(S473)
572and p-GSK3β(S9) in the MDA-MB436 restored cells upon
573exposure to ME0328 (Fig. 8c). Compared to untreated cells,
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Fig. 8 Pharmacologic inhibition
of PARP3 using ME0328
recapitulates effects of the
genetic disruption of PARP3. a
Dose response of ME0328 in the
parental MDA-MB231 (WT)
and the two PARP3−/−1 and
PARP3−/−3 MDA-MB231
knockout cell lines and in the
wild-type (WT) MDA-MB436
cells versus the PARP3−/−b and
PARP3−/−c MDA-MB436
clones. Results represent the
mean values of three
independent experiments ± SD.
*p < 0.05; **p < 0.01; ***p <
0.001. b Clonogenic survival of
the parental MDA-MB436 cells
and the PARP3−/−c MDA-
MB436 cell lines expressing
either the Flag control (Flag),
Flag-PARP3WT, or Flag-
PARP3HE either mock-treated or
exposed to ME0328 throughout
the experiment. Clonogenic
survival of the parental MDA-
MB436 cell line was set to
100%. Results represent the
mean values of three
independent experiments ± SD.
**p < 0.01. c The parental
MDA-MB436 (WT) and the
PARP3−/−c MDA-MB436 cell
lines expressing either the Flag
control (Flag), Flag-PARP3WT,
or Flag-PARP3HE were either
mock-treated or exposed to
ME0328 for 24 h and processed
for the analysis of
mTORC2 signaling by western
blotting using the appropriate
antibodies (upper panel). The
relative signal intensities of p-
Akt(S473) versus Akt, and p-
GSK3β(S9) versus GSK3β were
measured in three independent
experiments using ImageJ (right
panel). Mean values ± SD are
indicated. *p < 0.05
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574 ME0328 significantly decreased the levels of p-Akt(S473)
575 and p-GSK3β(S9) in WT and PARP3−/−c MDA-MB436
576 cells restored with Flag-PARP3WT, but had no effect on the
577 PARP3−/−c MDA-MB436 expressing the Flag tag only.
578 Similarly, ME0328 reduced the levels of p-Akt(S473) and
579 p-GSK3β(S9) in HCC1937 cells (Supplementary Fig. 7C).
580 Together, these results confirmed that the chemical inhibi-
581 tion of PARP3 reduces the survival and Rictor/mTORC2
582 activity in the context of BRCA1 deficiency specifically.
583 Discussion
584 Analysis of the published PARP3 gene expression profile
585 using the Cancer Cell Line Encyclopedia (CCLE) shows a
586 significantly higher expression of PARP3 in the TNBC
587 versus the non-TNBC cells, whereas PARP1 expression
588 remains similar (Supplementary Fig. 1). TNBC have a high
589 prevalence of BRCA1 mutations [34]. It has been demon-
590 strated previously that inhibition of Tankyrase 1 efficiently
591 reduces survival of BRCA1-associated cancers [20]. We
592 found that PARP3 stimulates Tankyrase 1 activity [8]. On
593 these bases, we hypothesized that targeting PARP3 may
594 provide a novel therapeutic avenue for BRCA1-deficient
595 TNBC.
596 We demonstrate here that the knockdown and knockout
597 of PARP3, or inhibition of its catalytic activity is selectively
598 lethal with BRCA1 in several experimental models of
599 TNBC. We discovered an unprecedented selective role of
600 PARP3 in the regulation of mTORC2 complex, a critical
601 Akt Ser473 kinase [7]. Although mTORC2 complex is
602 gaining attention as a relevant target for cancer therapy due
603 to its important functions in cell survival, cytoskeleton
604 organization, cell migration, and metabolism, its contribu-
605 tion in the progression of the BRCA1-deficient breast can-
606 cers has not yet been evaluated [6]. Here we provide robust
607 evidence that loss of PARP3 or inhibition of its catalytic
608 activity attenuates mTORC2-mediated Akt phosphorylation
609 especially in BRCA1-deficient cells that upregulate p-Akt
610 (S473) showing a lesser effect in cells with normal BRCA1
611 expression. The mechanism by which PARP3-catalyzed
612 ADP-ribosylation positively regulates mTORC2 appears to
613 be associated with the interaction of PARP3 with GSK3β
614 that might be required to temper the ubiquitination and
615 degradation of Rictor [35]. Rictor/mTORC2 pathway has
616 been reported to be an essential downstream branch of
617 TGFβ signaling representing a responsive target to inhibit
618 EMT [31]. We have shown that PARP3 drives TGFβ and
619 ROS-induced EMT, migration and stemness in breast can-
620 cer cells [14]. An important morphological modification
621 induced by TGFβ during migration involves the rearran-
622 gement of the cytoskeleton leading to formation of
623lamellipodia, a phenomenon elevated in BRCA1-deficient
624breast cancer cells and associated with increased activation
625of the small GTPases, RhoA and Rac1 [32, 36]. Rictor/
626mTORC2 plays a role in cytoskeleton reorganization and
627Rac1 has been involved [35, 37, 38]. We show here that
628PARP3 regulates these events in a context-dependent
629manner. Our data suggest that PARP3 promotes TGFβ-
630induced p-Akt(S473), RhoA activation and consequently
631migration irrespective of the BRCA1 context. These find-
632ings introduce signaling through RhoA as a downstream
633mechanism by which PARP3 may promote migration in
634breast cancer cells. In contrast, PARP3 supports enhanced
635Rac1 activation and lamellipodia formation in the context of
636BRCA1 deficiency reinforcing the hypothesis that targeting
637PARP3 could be beneficial to restrain BRCA1-associated
638cancer progression.
639Moreover, cumulative evidences point to a central role of
640mTORC2 signaling in the maintenance of genome integrity
641and deregulated p-Akt(S473) has been linked with surnu-
642merary centrosomes [39–41]. Accordingly, we found that
643the absence of PARP3 results in centrosome amplification
644and genomic instability as measured by the accumulation of
645micronuclei, telomeric aberrations and an increase in
646γH2AX and P-ATM levels that are intensified in the
647BRCA1-deficient cells (Supplementary Fig. 9). Hence, it is
648tempting to correlate abnormal centrosome numbers and
649genome instability with reduced Rictor/mTORC2 signaling
650in the absence of PARP3.
651In conclusion, we identified a new role of PARP3 cata-
652lyzed ADP-ribosylation in promoting Rictor/
653mTORC2 signaling and Rac1 GTPase activation specifi-
654cally in BRCA1-deficient TNBC cells emphasizing the
655potential clinical implications of selective PARP3 inhibi-
656tors. Accordingly, we demonstrate the efficacy and selec-
657tivity of the recently reported quinazoline derivative
658ME0328 as this compound compromises survival and
659mTORC2 signaling in the wild-type MDA-MB436 cells but
660not in the PARP3 knockout counterparts. These data
661exemplify PARP3 as a prominent target in a precision
662medicine approach and thus support the significant drug
663design efforts developed since a few years for selective
664targeting of PARPs in cancer therapy.
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